Investors are locking in gains in this fast-growing drugmaker.
These strategies can help you collect more money from Social Security in retirement.
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
The company's clinical trial is taking an important step forward.
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.
These companies could see their sales soar as seniors increasingly choose to live in their homes longer.
Delaying Social Security can result in a much bigger payday.
The company is raising more money from investors to support development of late-stage drugs.
Optimism is high that the company's lead pipeline candidate can secure an FDA OK.
Marijuana beverages, edibles, and vapes are finally available in Canada, but marijuana stocks still have big obstacles to overcome.
Investor optimism is surging following recent M&A in gene therapy.
The company unveiled positive data for the most advanced drug in its pipeline.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Industry watchers are skeptical that the company's lead drug candidate can succeed.
Investors went bargain-hunting with the embattled marketer of teeth-alignment solutions.
Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics
New data on Biogen's formerly shelved Alzheimer's disease drug puts it on a path toward blockbuster status, but it will have to win regulatory approval first.
Including one or more of these three top medical-device companies in your portfolio now could be savvy.
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
The maker of tubeless insulin pumps continues to deliver sales growth ahead of industry watchers' outlook.
This fast-growing medical device company just reported better-than-expected results.